Alterity Therapeutics
ATHE
10 hedge funds and large institutions have $361K invested in Alterity Therapeutics in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.
25% more funds holding
Funds holding: 8 → 10 (+2)
0% more ownership
Funds ownership: 0% → 0% (+0%)
28% less capital invested
Capital invested by funds: $503K → $361K (-$142K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$20.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$19.4K |
| 3 |
Morgan Stanley
New York
|
+$15K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$6.81K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$798 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$47.4K |
| 2 |
AIM
Advantage Investment Management
Cedar Rapids,
Iowa
|
-$80 |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
-$16 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $299K | +$15K | +939 | +4% |
|
|
OMC
2
Old Mission Capital
Chicago,
Illinois
| $17K | +$20.3K | +1,271 | New |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $16K | +$19.4K | +1,213 | New |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $15K | -$47.4K | -2,971 | -72% |
|
|
5
UBS Group
Zurich,
Switzerland
| $8K | +$6.81K | +427 | +206% |
|
|
AG
6
Advisor Group
Phoenix,
Arizona
| $3K | -$16 | -1 | -0.4% |
|
|
AIM
7
Advantage Investment Management
Cedar Rapids,
Iowa
| $1K | -$80 | -5 | -4% |
|
|
NFG
8
Next Financial Group
Houston,
Texas
| $1K | – | – | – |
|
|
9
Wells Fargo
San Francisco,
California
| $1K | +$798 | +50 | New |
|
|
APA
10
American Portfolios Advisors
Holbrook,
New York
| $109 | – | – | – |
|
ATHE Hedge Fund Activity: Q2 2019 in Review
10 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q2 2019, worth a combined $361K — down 28% from $503K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ATHE positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Old Mission Capital, opening a new position worth an estimated $20.3K. The largest seller was Susquehanna International Group, cutting an estimated $47.4K.
- 10 institutional investors held Alterity Therapeutics (ATHE) as of Q2 2019, up from 8 in Q1 2019.
- Funds reported $361K of Alterity Therapeutics stock for Q2 2019, down 28% quarter-over-quarter.
- 3 funds opened new Alterity Therapeutics positions in Q2 2019 and 0 closed out, a net change of +3 holders.
- The largest Alterity Therapeutics buyer in Q2 2019 was Old Mission Capital, an estimated $20.3K added.
- The largest Alterity Therapeutics seller in Q2 2019 was Susquehanna International Group, an estimated $47.4K sold.
Based on aggregated 13F filings for Q2 2019.